Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma Ltd. has announced the successful approval of all seven proposals presented at its Annual General Meeting of Shareholders on July 3, 2024. The proposals, detailed in a previous Notice and Proxy Statement, received the necessary majority votes from the shareholders. This marks a positive step forward for the company as it continues to align with shareholder expectations and strategic goals.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
